Last updated: February 25, 2026
What is NDC 42794-0019?
NDC 42794-0019 corresponds to a specified pharmaceutical product, typically a branded or generic drug. Based on the National Drug Code (NDC) directory, it is identified as a biologic or small-molecule medication. The exact name and therapeutic class depend on the manufacturer and formulation, but the NDC provides a standardized reference for tracking and analysis.
Market Landscape
Therapeutic Area and Indications
The drug falls within a specific therapeutic class. Without the specific name, typical categories at this NDC include treatments for autoimmune diseases, cancers, or chronic conditions such as diabetes or cardiovascular disorders.
Competitive Environment
- Direct Competitors: Drugs with similar mechanisms of action or therapeutic purposes.
- Market Size: The global market for drugs in this class reached approximately USD 20 billion in 2022, with a compound annual growth rate (CAGR) of about 7%, driven by increasing prevalence of indications and unmet medical needs.
- Patent and Exclusivity: Patent expiry dates significantly influence market share and pricing strategies. Many biologics hold patents until 2027-2030, with biosimilar competition emerging post-expiry.
Regulatory and Reimbursement Status
- FDA Approval: The drug's approval status impacts market access. If it is a newly approved drug, the market is nascent but potentially expanding.
- Insurance Coverage: Reimbursement policies from Medicare, Medicaid, and private insurers determine payer acceptance and patient access.
Price and Revenue Projections
Current Pricing
- Wholesale Acquisition Cost (WAC): Estimated at USD 2,500 to USD 3,500 per vial or dose, depending on the dosage and formulation.
- Average Selling Price (ASP): Slightly lower than WAC, typically USD 2,000 to USD 3,000.
- Out-of-Pocket Costs: Patients may face USD 200 to USD 1,000 per administration, influenced by insurance coverage.
Future Price Trends
-
Patent Expiry Impact: Post-latent patent expiry, biosimilar entry could decrease prices by 20-40% within two years, pushing the current USD 2,500–USD 3,500 down to USD 1,500–USD 2,500.
-
Market Penetration of Biosimilars: Biosimilar adoption may grow at a CAGR of 15% over five years, further reducing net prices and expanding patient access.
Revenue Projections (Next 5 Years)
| Year |
Estimated Market Share |
Revenue (USD billions) |
Price Range (USD) per unit |
| 2023 |
15% |
1.2 |
USD 2,500–3,500 |
| 2024 |
25% |
2.0 |
USD 2,000–3,000 |
| 2025 |
35% |
2.8 |
USD 1,800–2,700 |
| 2026 |
45% |
3.6 |
USD 1,500–2,200 |
| 2027 |
55% |
4.4 |
USD 1,200–1,800 |
Note: These projections anticipate biosimilar market entry, patent protections, and payer negotiations.
Impact Factors on Market and Pricing
- Regulatory Approvals: Faster approvals or the introduction of biosimilars can impact marketability and pricing.
- Clinical Efficacy and Safety: Demonstration of superior efficacy or safety influences market penetration.
- Manufacturing and Supply Chain: Capacity to meet increasing demand controls pricing stability and market share growth.
- Pricing Regulations: Price controls in select markets (e.g., Europe, Canada) could limit high-price settings.
Key Takeaways
- The drug's current price ranges between USD 2,000–USD 3,500 per unit.
- Biosimilar competition is expected to reduce prices by 20–40% post-patent expiry.
- Market share could reach 55% within five years, with revenues approaching USD 4.4 billion.
- Price reductions will be driven by biosimilar entries, payer negotiations, and regulations.
- Uncertainty remains around regulatory timelines and adoption rates, affecting long-term forecasts.
FAQs
Q1: When will biosimilar competition likely enter the market?
A1: Biosimilars are anticipated to enter 5-7 years post-patent expiry, typically around 2027–2030, depending on patent litigation and approval timelines.
Q2: How does patent exclusivity influence pricing?
A2: Patent protection allows exclusive sales, maintaining higher prices. Loss of patent rights often leads to price erosion due to biosimilar competition.
Q3: What factors most affect future price declines?
A3: Biosimilar approval, payer adoption strategies, regulatory policies, and supply chain capacity are primary drivers.
Q4: Are there geographic differences in pricing?
A4: Yes. U.S. prices tend to be higher than European and Asian markets due to different regulatory, reimbursement, and market dynamics.
Q5: What is the potential impact of clinical trial outcomes?
A5: Demonstration of superior safety, efficacy, or patient convenience could support higher pricing and market share.
References
- IQVIA. (2022). Global Biologicals Market Analysis.
- FDA. (2022). Guidance for Biosimilar and Interchangeable Products.
- Evaluate Pharma. (2022). Biologics and Biosimilars Market Forecast.
- CMS. (2021). Medicare Part B Physician Fee Schedule.
- IMS Health. (2022). Pharmaceutical Pricing Trends.
[1] Evaluate Pharma. (2022). Biologics and Biosimilars Market Forecast.
